Status:
COMPLETED
Efficacy and Safety Study of Neramexane to Treat Congenital and Acquired Nystagmus
Lead Sponsor:
Merz Pharmaceuticals GmbH
Conditions:
Nystagmus, Congenital Idiopathic
Nystagmus, Acquired
Eligibility:
All Genders
18-80 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to investigate the safety and efficacy of neramexane mesylate in the treatment of congenital idiopathic nystagmus (CIN) in comparison to placebo. In addition, a subgroup o...
Eligibility Criteria
Inclusion
- patients with congenital idiopathic nystagmus or acquired nystagmus subsequent to multiple sclerosis
- male or female outpatients
- aged between 18 and 80 years (inclusive) at screening
Exclusion
- patients with evidence of neurologic disorders other than CIN such as congenital nystagmus due to albinism or retinal diseases and/or acquired nystagmus (exemption: secondary to MS)
Key Trial Info
Start Date :
May 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
48 Patients enrolled
Trial Details
Trial ID
NCT00661440
Start Date
May 1 2008
Last Update
November 26 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Leicester, Leicester Royal Infirmary, Ophthalmology Group
Leicester, United Kingdom, LE2 7LX